Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. It is an oral, selective ACTH antagonist.
Atumelnant is now in Phase 2 of development and you can read the latest research results at the link below:
Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results From a12-Week, Phase 2, Open-Label Study
Richard J. Auchus, MD, PhD, Peter J. Trainer, MD, Kathryn Jean Lucas, MD3, et al
Poster: Annual Meeting of the Endocrine Society (ENDO); 6/03/2024
Click here to read more about Alumelnant on Crinetics’ website.
Recent Blog Posts
Medicine security – a national UK priority.
Concerns about medicines shortages in the UK have been highlighted in recent analysis from the House of Lords Public Services Committee and the Royal Pharmaceutical Society. The House of Lords Public Services Committee warns that medicines supply should be treated as...
2026 CAH Support Group Conference, 28th June, Sheffield
SUNDAY 28th JUNE 2026 9.30 -16:00 The Old Rectory, Handsworth, Sheffield, S13 9BZ theoldrectoryhandsworth.co.uk Those living with CAH and their families and friends are invited to the biennial conference of CAH Support Group. Visit our online booking page here to find...
A selection of articles from around the world in 2025
Here’s a selection of three articles from around the world in 2025 about CAH. They cover treatment methods and long term outcomes for people with CAH - making for interesting reading for anyone interested in or affected by CAH. These articles are not a recommendation...